Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism

Sunday, October 8, 2017 | 1:30 – 1:50 PM | 20 min

MUHAMED SARIĆ, MD, PHD
Director of Echocardiography Lab
Associate Professor of Medicine
New York University Langone Medical Center
Disclosures

Medtronic & Philips Speakers’ Bureaus
ASE Guidelines Related to Stroke

There are several recent ASE guidelines related to echocardiography in patients with stroke and systemic embolism:

- **2015** Multimodality Imaging of Diseases of the Thoracic Aorta in Adults
- **2015** Guidelines for the Echocardiographic Assessment of Atrial Septal Defect & Patent Foramen Ovale
- **2016** Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism
GUIDELINES AND STANDARDS

Multimodality Imaging of Diseases of the Thoracic Aorta in Adults: From the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance

Steven A. Goldstein, MD, Co-Chair, Arturo Evangelista, MD, FESC, Co-Chair, Suhny Abbara, MD, Andrew Arai, MD, Federico M. Asch, MD, FASE, Luigi P. Badano, MD, PhD, FESC, Michael A. Bolen, MD, Heidi M. Connolly, MD, Hug Cuéllar-Calabria, MD, Martin Czerny, MD, Richard B. Devereux, MD, Raimund A. Erbel, MD, FASE, FESC, Rossella Fattori, MD, Eric M. Isselbacher, MD, Joseph M. Lindsay, MD, Marti McCulloch, MBA, RDCS, FASE, Hector I. Micheleana, MD, FASE, Christoph A. Nienaber, MD, FESC, Jae K. Oh, MD, FASE, Mauro Pepi, MD, FESC, Allen J. Taylor, MD, Jonathan W. Weinsaft, MD, Jose Luis Zamorano, MD, FESC, FASE, Contributing Editors: Harry Dichtig, MD, Kim Eagle, MD, John Elefteriades, MD, Guillaume Jondeau, MD, PhD, FESC, Hervé Rousseau, MD, PhD, and Marc Schepens, MD, Washington, District of Columbia; Barcelona and Madrid, Spain; Dallas and Houston, Texas; Bethesda and Baltimore, Maryland; Padua, Pesaro, and Milan, Italy; Cleveland, Ohio; Rochester, Minnesota; Zurich, Switzerland; New York, New York; Essen and Rostock, Germany; Boston, Massachusetts; Ann Arbor, Michigan; New Haven, Connecticut; Paris and Toulouse, France; and Brugge, Belgium

(J Am Soc Echocardiogr 2015;28:119-82.)
VII. Atherosclerosis

Various terms have been used to describe the appearance of atherosclerotic lesions of the aorta on imaging. The simplest lesions are usually reported as “atheroma” or “atheromatous plaque.” When mobile components are seen attached to these plaques, the terms ruptured plaque, mobile plaque, mobile debris, and superimposed thrombi are used. Some believe that mobile echodensities represent fibrous caps of ruptured plaques, but autopsy and surgically examined specimens indicate that they are most often superimposed thrombi. Supporting the latter conclusion, mobile lesions have been shown to disappear after anticoagulant therapy. Both necropsy and TEE have demonstrated that the frequency and severity of atherosclerotic plaque is lowest in the ascending aorta, greater in the arch, and greatest in the descending thoracic aorta.
ASE GUIDELINES & STANDARDS

Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions

Frank E. Silvestry, MD, FASE, Chair, Meryl S. Cohen, MD, FASE, Co-Chair, Laurie B. Armsby, MD, FSCAI, Nitin J. Burkule, MD, DM, FASE, Craig E. Fleishman, MD, FASE, Ziyad M. Hijazi, MD, MPH, MSc, Roberto M. Lang, MD, FASE, Jonathan J. Rome, MD, and Yan Wang, RDCS, Philadelphia, Pennsylvania; Portland, Oregon; Thane, India; Orlando, Florida; Doha, Qatar; and Chicago, Illinois

(J Am Soc Echocardiogr 2015;28:910-58.)
ASE GUIDELINES AND STANDARDS

Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism

Muhamed Saric, MD, PhD, FASE, Chair, Alicia C. Armour, MA, BS, RDCS, FASE, M. Samir Arnaout, MD, Farooq A. Chaudhry, MD, FASE, Richard A. Grimm, DO, FASE, Itzhak Kronzon, MD, FASE, Bruce F. Landeck, II, MD, FASE, Kameswari Maganti, MD, FASE, Hector I. Michalena, MD, FASE, and Kirsten Tolstrup, MD, FASE, New York, New York; Durham, North Carolina; Beirut, Lebanon; Cleveland, Ohio; Aurora, Colorado; Chicago, Illinois; Rochester, Minnesota; and Albuquerque, New Mexico

ASE Guidelines Committee: Cardiac Source of Embolism

Kameswari Maganti
Northwestern, Chicago

Hector Michelena
Mayo Clinic

Kirsten Tolstrup
U. of New Mexico

Muhamed Sarić
New York University
Guidelines Committee Chair
2016 ASE Embolism Guidelines | Overall Design

- 2016 ASE guidelines on cardiac source of embolism are the first set of guidelines from the American Society of Echocardiography specific to this topic.

- Clinical utility of the 2016 guidelines is illustrated through figures, tables, and videos, which include imaging techniques, strategies for overall evaluation, reporting recommendations, and comparisons of echo modalities.

- 2016 ASE embolism guidelines are harmonized with the 2011 Appropriate Use Criteria for Echocardiography.
Guidelines Rationale

- **Cardiac embolism** accounts for a large number of *ischemic* strokes and systemic emboli.

- **Paradoxical embolism** and embolism from the thoracic aorta, especially of its atheroma contents, is responsible for additional cases of stroke and systemic embolism.

- There were **no prior guidelines** from the American Society of Echocardiography specific to this topic.
Guidelines Clinical Utility

- **Diagnosis**
  Transthoracic and transesophageal echocardiography serve as a cornerstone in the evaluation, diagnosis, and management of these patients.

- **Management**
  A clear understanding of the various types of cardiovascular conditions associated with cardioembolic stroke and their intrinsic risk is needed to manage and diagnose cardiac sources of embolism.
Guidelines Overview

• Review potential cardiac sources of embolism

• Discuss the role of echocardiography in clinical management of cardioembolic stroke and systemic embolism

• Compare echocardiography to other imaging modalities used for diagnosis of cardiac sources of emboli

• Provide levels of recommendation:
  • ECHOCARDIOGRAPHY RECOMMENDED
  • ECHOCARDIOGRAPHY POTENTIALLY USEFUL
  • ECHOCARDIOGRAPHY NOT RECOMMENDED
Recommendations for Performance of Echocardiography in Patients with Potential Cardiac Source of Embolism

**Echocardiography Recommended**
- Echocardiography should be considered in all patients with suspected cardiac sources of embolism, especially in patients for whom clinical therapeutic decisions (such as anticoagulation or cardioversion) will depend on echocardiographic findings.

**Echocardiography Potentially Useful**
- Patients with neurologic events and concomitant intrinsic cerebrovascular disease.

**Echocardiography Not Recommended**
- Echocardiography is not recommended in patients for whom the results will not guide therapeutic decisions.

**TTE versus TEE**
- TEE is not indicated when transthoracic echocardiographic findings are diagnostic for a cardiac source of embolism.
- TTE may be unnecessary when TEE is already planned (e.g., for evaluation of intracardiac masses, prosthetic valves, and thoracic aorta or when TEE is used to guide a percutaneous procedure related to cardiac source of embolism).
STROKE: BASIC STATISTICS

- Stroke is a leading cause of death and disability worldwide
- In 2005, it was estimated that stroke accounts for 10% of all deaths worldwide
- More than 2,000 new strokes occur every day in the United States
- Stroke incidence is declining in developed countries, largely due to better hypertension control and less tobacco use

However, the absolute number of strokes will continue to rise because of the aging population

*Neurol Clin 2008;26:871–895
JAMA 2006;296(24):2939–46*
STROKE TYPES

Based on data from a large Danish study of ~40,000 stroke patients. *Stroke 2009;40:2068-2072*

**Ischemic Strokes**

~90%

Ischemic ‘mini-strokes’ that resolve spontaneously within 24-48 hours are called **transient ischemic attacks (TIAs)**.

**Hemorrhagic Strokes**

~10%

Some hemorrhagic strokes start as ischemic strokes but later undergo hemorrhagic conversion.
## ISCHEMIC STROKE SUBTYPES

### TOAST CRITERIA

**Trial of Org 10172 in Acute Stroke Treatment**

*Stroke* 1993;24:35-41

**Org 10172** was a code name for danaparoid, a heparin-like drug used in the trial.

<table>
<thead>
<tr>
<th>TOAST Subtype</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. LARGE VESSEL STROKE</strong></td>
<td>Significant stenosis or occlusion of a large cervical or cerebral artery presumably due to atherosclerosis</td>
</tr>
<tr>
<td><strong>2. CARDIOEMBOLIC STROKE</strong></td>
<td>Cerebral vessel occlusion due to embolus arising in the heart (and thoracic aorta)</td>
</tr>
<tr>
<td><strong>3. SMALL-VESSEL STROKE</strong></td>
<td>Lacunar brain infarcts</td>
</tr>
<tr>
<td><strong>4. CRYPTOGENIC STROKE</strong></td>
<td>Stroke of unknown cause</td>
</tr>
<tr>
<td><strong>5. STROKE DUE TO OTHER KNOWN CAUSES</strong></td>
<td>Vasculopathies, hypercoagulable states etc.</td>
</tr>
</tbody>
</table>
## Ischemic Stroke Subtypes

### Relative Prevalence of Ischemic Strokes in Rochester, Minnesota

*(N = 454; 1985-1989)*

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Large Vessel Stroke</td>
<td>16%</td>
</tr>
<tr>
<td>2. Cardioembolism</td>
<td>29%</td>
</tr>
<tr>
<td>3. Small Vessel Stroke</td>
<td>16%</td>
</tr>
<tr>
<td>4. Cryptogenic</td>
<td>36%</td>
</tr>
<tr>
<td>5. Other known causes</td>
<td>3%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

- Approximately 1/3 of ischemic strokes are likely cardioembolic.
- Some cryptogenic strokes may be cardioembolic.

*Stroke 1999;30:2513-2516*
Cardiac Source and Risk of Embolism

Cardiac sources differ in their embolic potential

**HIGH-RISK POTENTIAL**

- **THROMBI**
  - Atrial fibrillation
  - Myocardial infarction
  - Cardiomyopathies
  - Mechanical prosthetic valves

- **VEGETATIONS**
  - Valvular and nonvalvular infective endocarditis

- **TUMORS**
  - Myxoma
  - Papillary fibroelastoma

- **AORTIC AHEROMA**

**MODERATE-RISK POTENTIAL**

- **THROMBI & SIMILAR PATHOLOGIES**
  - ‘Smoke’ and ‘Sludge’
  - Mitral stenosis with sinus rhythm
  - Atrial flutter

- **VALVULAR DISEASE**
  - Bioprosthetic valves
  - Giant Lambl’s excrescence
  - Calcific aortic stenosis
  - Mitral annular calcifications
  - Mitral valve prolapse
  - Nonbacterial thrombotic endocarditis

- **ATRIAL SEPTUM**
  - Atrial septal aneurysm
  - Patent foramen ovale

*Stroke* 1993;24:35-41
HOW DO CLINICIANS SUSPECT A CARDIOEMBOLIC STROKE?

BRAIN
• Sudden onset of often severe neurologic deficit without prodromes
• Multiple brain lesion in multiple vascular territories
• Recurrent strokes (waves of emboli) over a short period of time

PRESUMED CARDIAC SOURCE OF EMBOLI

OTHER ARTERIAL TERRITORIES
• Spleen, kidney or other organ infarcts occurring at time of strokes support cardioembolic mechanism
The patient first had an embolic stroke to the right middle cerebral artery territory (thick arrows).

Three weeks later, the patient had a new stroke in the territory of the left middle cerebral artery (thin arrow).
**Brain MRI: Nonembolic Strokes**

Thick arrow points to a *watershed infarct* at the boundary of right anterior and right middle cerebral artery territories in a middle-aged woman with headache.

Thin arrow points to a *lacunar infarct* in the left frontal paraventricular region of a patient with systemic hypertension.
APPROPRIATE USE OF ECHOCARDIOGRAPHY

ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography

A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians

(J Am Soc Echocardiogr 2011;24:229-67.)

Keywords: ACCF Appropriate Use Criteria, Cardiac imaging, Coronary artery disease, Diagnostic testing, Echocardiography
ECHO IN CARDIAC SOURCE OF EMBOLISM | APPROPRIATE USE

**Appropriate Use: Transthoracic Echocardiography (TTE)**
- Symptoms or conditions potentially related to suspected cardiac etiology, including but not limited to chest pain, shortness of breath, palpitations, TIA, stroke, or peripheral embolic event
- Suspected cardiac mass
- Suspected cardiovascular source of embolus
- Initial evaluation of suspected infective endocarditis (IE) with positive blood culture results or new murmur
- Reevaluation of IE at high risk for progression or complication or with a change in clinical status or cardiac examination results
- Known acute pulmonary embolism (PE) to guide therapy (e.g., thrombectomy and thrombolytic therapy)
- Reevaluation of known PE after thrombolysis or thrombectomy for assessment of change in right ventricular (RV) function and/or pulmonary artery pressure

**Appropriate Use: TEE**
- As initial or supplemental test for evaluation for cardiovascular source of embolus with no identified noncardiac source
- As initial or supplemental test to diagnose IE with a moderate or high pretest probability (e.g., staph bacteremia, fungemia, prosthetic heart valve, or intracardiac device)
- As initial test for evaluation to facilitate clinical decision making with regard to anticoagulation, cardioversion, and/or radiofrequency ablation
Echo in Cardiac Source of Embolism | Inappropriate Use

**Inappropriate Use: TTE**
- Transient fever without evidence of bacteremia or new murmur
- Transient bacteremia with a pathogen not typically associated with IE and/or a documented nonendovascular source of infection
- Routine surveillance of uncomplicated IE when no change in management is contemplated
- Suspected PE to establish diagnosis
- Routine surveillance of prior PE with normal RV function and pulmonary artery systolic pressure

**Inappropriate Use: TEE**
- Evaluation for cardiovascular source of embolus with a known cardiac source in which TEE would not change management
- Routine use of TEE when diagnostic TTE is reasonably anticipated to resolve all diagnostic and management concerns
- Surveillance of prior transesophageal echocardiographic finding for interval change (e.g., resolution of thrombus after anticoagulation, resolution of vegetation after antibiotic therapy) when no change in therapy is anticipated
- To diagnose IE with low pretest probability (e.g., transient fever, known alternative source of infection, negative blood culture results or atypical pathogen for endocarditis)
- Evaluation when a decision has been made to anticoagulate and not to perform cardioversion
Cardiac Source of Embolism

LEFT VENTRICULAR THROMBUS


**LEFT VENTRICULAR THROMBUS**

**Basic Characteristics**

- Typically, LV thrombus is associated with a hypokinetic, akinetic or aneurysmal LV segment.
- LV thrombi can be seen in both ischemic and nonischemic cardiomyopathy.
- Ischemic LV thrombi can occur with either acute myocardial infarction or after chronic remodeling of LV (such as LV aneurysm).

**Imaging Recommendations**

- Because LV is in anterior chest, LV thrombi are typically well seen on **transthoracic echocardiography** (TTE).
- Use of **microbubble (transpulmonary) contrast agents** enhances the diagnosis of LV thrombi.
LEFT VENTRICULAR THROMBUS

Highlights

• ISCHEMIC CARDIOMYOPATHY
  Prior to modern therapy:
  • 35% of patients with recent anterior wall MI would develop mural thrombi if not anticoagulated
  • 40% of them would embolize systemically within 4 months after the MI in the absence of anticoagulation

• NONISCHEMIC CARDIOMYOPATHY
  • 3.5% annual embolic risk
**LEFT VENTRICULAR THROMBUS**

**Clinical History**

- 24-year-old man with acute anterior wall MI 3 weeks earlier
- Now presents with stroke AND bilateral lower extremity thromboemboli

EKG consistent with completed anteroseptal wall MI
(Q waves in V1-V3)
**LEFT VENTRICULAR THROMBUS**

**APICAL 4-CHAMBER VIEW**

Arrow points to a large (3.1 x 2.2 cm) LV apical thrombus in this patient with recent LAD infarct.
**LEFT VENTRICULAR THROMBUS**

**Clinical History**

- 52-year-old woman with nonischemic cardiomyopathy
- Now presents with recent sudden onset of left sided weakness

**APICAL 4-CHAMBER VIEW ZOOMED TO LV APEX**

BEFORE microbubble injection

AFTER microbubble injection
LEFT VENTRICULAR THROMBUS

APICAL 4-CHAMBER VIEW ZOOMED TO LV APEX

BEFORE microbubble injection

AFTER microbubble injection
(Note the absence of contrast uptake by the thrombus)
[A] Apical four-chamber view of a noncontrast transthoracic echocardiographic study demonstrates a large LV apical thrombus (arrow).

[B] The same patient as in (A) was then imaged using transpulmonary microbubble echocardiographic contrast. The LV apical thrombus, lacking vascular supply, appears black (arrow) on contrast imaging.

[C] Apical three-chamber view demonstrates a mobile LV thrombus (arrow) attached to the apical portion of the anterior interventricular septum.
ASE GUIDELINES | CARDIAC SOURCE OF EMBOLISM

Recommendations for Performance of Echocardiography in Patients with Suspected LV Thrombus

Echocardiography Recommended
- TTE is recommended for the evaluation of patients with underlying cardiac disease known to predispose to LV thrombus formation (such as myocardial infarction or nonischemic cardiomyopathy).
- TTE is typically superior to TEE in the assessment of LV apical thrombus.

Echocardiography Potentially Useful
- Contrast echocardiography using microbubble agents (such as perflutren) may aid in detecting LV thrombi and may help differentiate avascular thrombi from vascular tumors.
- Three-dimensional echocardiography may provide more precise assessment of LV thrombus.

Echocardiography Not Recommended
- Echocardiography is not recommended in patients for whom the results will not guide therapeutic decisions.
Cardiac Source of Embolism

LEFT VENTRICULAR TUMOR VS. THROMBUS
LEFT VENTRICULAR LYMPHOMA

Clinical History

• 41-year-old woman HIV-associated Burkitt’s lymphoma

Apical 4-chamber View Post Microbubble Injection

Arrow points to a large (2.7 x 1.5 cm) LV lymphoma

Note the contrast uptake by the tumor; thrombi typically do NOT opacify with microbubble contrast
LEFT VENTRICULAR LYMPHOMA

APICAL 4-CHAMBER VIEW POST MICROBUBBLE INJECTION

Note the preserved LV contractility;
a mass in a normally contracting LV is more likely to be a tumor than a thrombus
2 Patients with LV Mass | Microbubble Injection

**Patient #1**
LV thrombus post LAD infarct

**Patient #2**
LV lymphoma in an AIDS patient
**Teaching Points**

Differential diagnosis of an LV mass:

**LV Thromus**

1. Adjacent to akinetic/hypokinetic LV segment
2. Does NOT take up microbubble contrast

**LV Tumor**

1. Typically no primary LV wall motion abnormalities
2. Typically DOES take up microbubble contrast
Cardiac Source of Embolism

AORTIC ATHEROMA
CARDIAC SOURCE OF EMBOLISM: AORTICATHEROMA

Basic Features

• Atheromatous plaque in ascending aorta and aortic arch is a well established source of systemic embolism

• The risk of embolism is related to plaque thickness and plaque complexity. High risk features include:
  • Plaque thickness $> 4 \text{ mm}$
  • Plaque ulcerations
  • Mobile components which represent superimposed thrombi

• Plaque from descending aorta can also embolize retrogradely into the neck vessels during diastolic flow reversal in the aorta

• Plaque in the ascending aorta and arch typically cannot be fully evaluated by transthoracic echocardiography

Imaging Recommendations

• Transesophageal echocardiography is the primary echocardiographic means of diagnosing and characterizing aortic plaques
AORTIC ARCH: NORMAL VS. SEVERE PLAQUE

Normal Arch

Severe Calcified Plaque
AORTIC ARCH: NORMAL VS. SEVERE PLAQUE

<<< Normal Arch

Severe Plaque >>>
AORTIC ARCH: COMPLEX PLAQUE

Ulcerated Plaque

Mobile Plaque
AORTIC ARCH: ULCERATED VS. MOBILE PLAQUE

Ulcerated Plaque

Mobile Plaque
Aortic Arch on 3D TEE: Normal vs. Ulcerated Plaque

Normal Arch

Ulcerated Plaque
### Table 9: Classification of atherosclerotic plaques

<table>
<thead>
<tr>
<th>Onset</th>
<th>Stage</th>
<th>Clinical manifestations</th>
<th>Lesion name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early lesions</td>
<td>I</td>
<td>Typically silent</td>
<td>Initial lesion</td>
<td>Small amounts of intracellular lipid deposits</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>fatty streak</td>
<td></td>
<td>Larger amounts of intracellular lipid deposits</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>intermediate lesion</td>
<td></td>
<td>Small extracellular lipid deposits</td>
</tr>
<tr>
<td>Late lesions</td>
<td>IV</td>
<td>Silent or clinically overt</td>
<td>Atheroma</td>
<td>Extracellular lipid core</td>
</tr>
<tr>
<td></td>
<td>V</td>
<td></td>
<td>Fibroatheroma</td>
<td>Lipid core with fibrotic changes</td>
</tr>
<tr>
<td></td>
<td>VI</td>
<td>Complex plaque</td>
<td></td>
<td>Surface defects such as ulcerations, hemorrhage and thrombus; mobile plaque, a marker of severe atherosclerosis, is mostly made of thrombi</td>
</tr>
</tbody>
</table>

ASE Guidelines | Cardiac Source of Embolism
AORTIC ATHEROMA
2D & 3D TEE
Recommendations for Echocardiographic Evaluation of Aortic Sources of Embolism

Echocardiography Recommended
• TEE is the preferred echocardiographic method for the evaluation of aortic sources of emboli.

Echocardiography Potentially Useful
• Aortic plaque may occasionally be seen on TTE. However, TTE has low sensitivity for the detection of aortic pathology, including aortic plaques, compared with TEE.

Echocardiography Not Recommended
• Echocardiography is not recommended in patients for whom the results will not guide therapeutic decisions
Recommendations for Echocardiography in Patients Referred for Cardiac Surgery or Percutaneous Intervention

Echocardiography Recommended

- TEE or intracardiac echocardiography is recommended in all patients before intracardiac percutaneous intervention to exclude potential cardiac sources of emboli that might be dislodged during intervention.
- The routine preoperative use of TEE to identify and manage aortic atheromatous disease is recommended in patients with increased risk for embolic stroke, including those with histories of cerebrovascular or peripheral vascular disease and those with evidence of aortic atherosclerosis or calcification by other imaging modalities, including preoperative or intraoperative MRI, CT, or chest radiography. TEE may allow the surgeon to individualize the surgical technique and potentially reduce the incidence of embolic stroke.
GUIDELINES AND STANDARDS

Multimodality Imaging of Diseases of the Thoracic Aorta in Adults: From the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance

Steven A. Goldstein, MD, Co-Chair, Arturo Evangelista, MD, FESC, Co-Chair, Suhny Abbara, MD, Andrew Arai, MD, Federico M. Asch, MD, FASE, Luigi P. Badano, MD, PhD, FESC, Michael A. Bolen, MD, Heidi M. Connolly, MD, Hug Cuéllar-Calàbia, MD, Martin Czerny, MD, Richard B. Devereux, MD, Raimund A. Erbel, MD, FASE, FESC, Rossella Fattori, MD, Eric M. Isselbacher, MD, Joseph M. Lindsay, MD, Marti McCulloch, MBA, RDCS, FASE, Hector I. Michelela, MD, FASE, Christoph A. Nienaber, MD, FESC, Jae K. Oh, MD, FASE, Mauro Pepi, MD, FESC, Allen J. Taylor, MD, Jonathan W. Weinsaft, MD, Jose Luis Zamorano, MD, FESC, FASE, Contributing Editors: Harry Dietz, MD, Kim Eagle, MD, John Elefteriades, MD, Guillaume Jondeau, MD, PhD, FESC, Hervé Rousseau, MD, PhD, and Marc Schepens, MD, Washington, District of Columbia; Barcelona and Madrid, Spain; Dallas and Houston, Texas; Bethesda and Baltimore, Maryland; Padua, Pesaro, and Milan, Italy; Cleveland, Ohio; Rochester, Minnesota; Zurich, Switzerland; New York, New York; Essen and Rostock, Germany; Boston, Massachusetts; Ann Arbor, Michigan; New Haven, Connecticut; Paris and Toulouse, France; and Brugge, Belgium

(J Am Soc Echocardiogr 2015;28:119-82.)
Cardiac Source of Embolism

PEDIATRIC POPULATION
STROKE IN THE PEDIATRIC POPULATION

Stroke is rare in young adults (<50 years of age) and even less common in the pediatric population. Studies have shown that the annual incidence of stroke in young adults ranges from 10 to 23 cases per 100,000 persons per year.\textsuperscript{216,217} In children, after excluding stroke due to perinatal trauma, the incidence is lower at about two or three cases per 100,000 persons per year.\textsuperscript{218} Of these cases, 24\% to 57\% are thought to have embolic causes.\textsuperscript{219} Embolic stroke in children can be due to hypercoagulable conditions or paradoxical embolus due to intracardiac or intravascular shunt. As in adults, strokes in pediatric patients may also be due to left-heart lesions with embolic potential, such as vegetations, tumors, and thrombi.

Many diseases predispose to hypercoagulability in children. Among the most common is sickle-cell disease, which has a 220 times higher annual incidence of stroke than the normal population.\textsuperscript{220} Others include protein C deficiency, homocysteinuria, thrombotic thrombocytopenia purpura, and hyperlipidemia.

Certain congenital heart defects with intracardiac or intravascular shunt lesions predispose children to embolic stroke. Paradoxical embolism is discussed elsewhere in these guidelines, so the focus here is on the anatomic factors predisposing to embolic stroke in children. Among these, ASD and PFO receive the most attention.
ASE GUIDELINES | CARDIAC SOURCE OF EMBOLISM

PATENT FORAMEN OVALE
PEDIATRIC 2D TEE | AGITATED SALINE INJECTION

Atrial Septum
LA
RA

Onset of Flow Across PFO

Opacification of LA

PFO
LA
RA

LA
RA
Paradoxical Embolus Across Interatrial Septum
Pediatric 2D TEE
Recommendations for Echocardiography in Pediatric Patients with Suspected Systemic Embolism

**Echocardiography Recommended**
- TTE is recommended in all children in whom embolic stroke is suspected.
- Agitated saline contrast bubble study may be necessary to determine right-to-left shunt pathway.
- Echocardiographic imaging in children with suspected cardiac source of embolism should be performed at a pediatric laboratory.

**Echocardiography Potentially Useful**
- TEE for evaluation of embolic stroke should be rare in children and is recommended only when TTE windows are poor.
ASE GUIDELINES & STANDARDS

Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions

Frank E. Silvestry, MD, FASE, Chair, Meryl S. Cohen, MD, FASE, Co-Chair, Laurie B. Armsby, MD, FSCAI, Nitin J. Burkule, MD, DM, FASE, Craig E. Fleishman, MD, FASE, Ziyad M. Hijazi, MD, MPH, MScA, Roberto M. Lang, MD, FASE, Jonathan J. Rome, MD, and Yan Wang, RDCS, Philadelphia, Pennsylvania; Portland, Oregon; Thane, India; Orlando, Florida; Doha, Qatar; and Chicago, Illinois

(J Am Soc Echocardiogr 2015;28:910-58.)
Thank you

New York University Medical Center